"HEK293 Cells" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line generated from human embryonic kidney cells that were transformed with human adenovirus type 5.
| Descriptor ID |
D057809
|
| MeSH Number(s) |
A11.251.210.172.750 A11.436.334
|
| Concept/Terms |
HEK293 Cells- HEK293 Cells
- Cell, HEK293
- Cells, HEK293
- HEK293 Cell
- 293T Cells
- 293T Cell
- Cell, 293T
- Cells, 293T
- HEK 293 Cells
- 293 Cell, HEK
- 293 Cells, HEK
- Cell, HEK 293
- Cells, HEK 293
- HEK 293 Cell
- Human Kidney Cell Line 293
- Human Embryonic Kidney Cell Line 293
- HEK 293 Cell Line
|
Below are MeSH descriptors whose meaning is more general than "HEK293 Cells".
Below are MeSH descriptors whose meaning is more specific than "HEK293 Cells".
This graph shows the total number of publications written about "HEK293 Cells" by people in this website by year, and whether "HEK293 Cells" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 4 | 4 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 4 | 4 |
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 3 | 3 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 4 | 4 |
| 2019 | 0 | 3 | 3 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 4 | 4 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HEK293 Cells" by people in Profiles.
-
Heterologous Immunization with Improved HIV-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After SHIV Challenge. Viruses. 2025 Feb 17; 17(2).
-
A promising class of antiprotozoal agents, design and synthesis of novel Pyrimidine-Cinnamoyl hybrids. Eur J Med Chem. 2025 Jan 05; 281:116944.
-
Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination. Front Immunol. 2023; 14:1231276.
-
HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6. Virol J. 2022 09 07; 19(1):143.
-
SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity. Cell Rep Med. 2022 02 15; 3(2):100510.
-
Myricetin inhibits breast and lung cancer cells proliferation via inhibiting MARK4. J Cell Biochem. 2022 02; 123(2):359-374.
-
Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth. Front Immunol. 2021; 12:734110.
-
Improved Specificity and Safety of Anti-Hepatitis B Virus TALENs Using Obligate Heterodimeric FokI Nuclease Domains. Viruses. 2021 07 12; 13(7).
-
Design and synthesis of quinoline-pyrimidine inspired hybrids as potential plasmodial inhibitors. Eur J Med Chem. 2021 May 05; 217:113330.
-
In Vivo Delivery of Cassettes Encoding Anti-HBV Primary MicroRNAs Using an Ancestral Adeno-Associated Viral Vector. Methods Mol Biol. 2020; 2115:171-183.